| Quarterly Financials | Mar 2015 | Dec 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 35 | 23 | 30 | 32 | 39 | 34 | 36 | 46 | 58 | 26 | 28 | 28 | 56 | 15 | 69 | 16 | 19 | 18 | 31 | 23 | 101 | 21 | 23 | 23 | 97 | 33 | 39 | 40 | 80 | 42 | 51 | 53 | 119 | 62 | 63 | 53 |
| Expenses | 33 | 31 | 30 | 30 | 34 | 26 | 33 | 36 | 27 | 21 | 22 | 25 | 21 | 13 | 12 | 13 | 14 | 11 | 25 | 17 | 17 | 16 | 15 | 17 | 26 | 20 | 34 | 26 | 22 | 28 | 25 | 30 | 33 | 32 | 33 | 30 |
| EBITDA | 2 | -8 | 1 | 2 | 5 | 8 | 3 | 10 | 31 | 5 | 6 | 3 | 35 | 2 | 57 | 4 | 5 | 7 | 6 | 6 | 84 | 6 | 7 | 6 | 70 | 13 | 5 | 14 | 58 | 14 | 26 | 22 | 85 | 31 | 30 | 23 |
| Operating Profit % | -2 % | -37 % | -6 % | 2 % | 4 % | 15 % | 0 % | 19 % | 19 % | 13 % | 13 % | 5 % | 11 % | -1 % | -6 % | 6 % | 15 % | 27 % | 14 % | 20 % | 15 % | 19 % | 16 % | 25 % | 30 % | 34 % | 8 % | 30 % | 31 % | 30 % | 49 % | 40 % | 37 % | 46 % | 45 % | 39 % |
| Depreciation | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 3 | -6 | -2 | 1 | 3 | 8 | 3 | 9 | 30 | 4 | 5 | 2 | 35 | 1 | 56 | 3 | 4 | 6 | 5 | 5 | 83 | 4 | 6 | 4 | 68 | 11 | 3 | 12 | 56 | 11 | 24 | 19 | 82 | 27 | 27 | 20 |
| Tax | -22 | -81 | -27 | -25 | -27 | -36 | -31 | -25 | -58 | -49 | -51 | -35 | -74 | -67 | -60 | -86 | -93 | -80 | -67 | -44 | -37 | -48 | 5 | 23 | -47 | -35 | -45 | -33 | -35 | -51 | -48 | -37 | -39 | -38 | -42 | -42 |
| Net Profit | 25 | 75 | 25 | 26 | 30 | 44 | 33 | 34 | 88 | 53 | 56 | 37 | 109 | 68 | 115 | 89 | 97 | 86 | 72 | 49 | 120 | 52 | 1 | -19 | 115 | 46 | 48 | 44 | 91 | 61 | 72 | 56 | 121 | 65 | 69 | 62 |
| EPS in ₹ | 0.92 | 2.80 | 0.93 | 0.97 | 1.13 | 1.64 | 1.24 | 1.28 | 3.41 | 2.05 | 2.15 | 1.43 | 4.24 | 2.65 | 4.50 | 3.45 | 3.77 | 3.33 | 2.80 | 1.91 | 4.68 | 2.02 | 0.04 | -0.72 | 4.49 | 1.78 | 1.88 | 1.73 | 3.53 | 2.39 | 2.81 | 2.17 | 4.71 | 2.55 | 2.67 | 2.40 |
Alembic
Alembic
99.70
-0.72
(-0.72%)
Key Fundamentals
Market Cap
2,560.11 Cr
EPS
12.10
PE Ratio
8.12
Dividend Yield
2.40 %
Industry
Realty 52 Week High
153.39
52 Week Low
85.46
PB Ratio
1.10
Debt to Equity
0.01
Actual
Company News
View All News
Alembic Pharmaceuticals received USFDA final approval for its Ticagrelor tablets (60mg) used to reduce cardiovascular death, heart attack, and stroke risks in patients with acute coronary syndrome or heart attack history. The tablets are therapeutically equivalent to AstraZeneca's Brilinta Tablets and have an estimated market size of $236 million for 12 months ending June 2025. The company previously received approval for the 90mg strength and now holds 227 total ANDA approvals from USFDA. Alembic Pharma shares traded flat at ₹905.15, down 13.7% year-to-date.
Alembic Pharmaceuticals received final USFDA approval for its generic version of Triamcinolone Acetonide Injectable Suspension USP 40 mg/mL. The approved product is a corticosteroid formulation used for joint-injection and intralesional administration. This approval brings Alembic's total ANDA approvals to 227, comprising 206 final approvals and 21 tentative approvals. The company expects this approval to contribute to its U.S. generics business growth and support its goal of capturing greater market share in North American regulated markets.
Alembic Pharmaceuticals received final approval from the US Food & Drug Administration for its generic version of Paroxetine extended-release tablets in 25 mg and 37.5 mg strengths. The approved drug is therapeutically equivalent to Apotex Inc's reference product Paxil CR extended-release tablets. The medication is indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
761.50 | #1 1,88,495.24 | 42.86 | 8,995.90 | 29.28 | 2,695 | -14.56 | 60.17 | |
1,196.60 | 1,19,474.94 | 39.46 | #1 14,169.80 | 35.34 | #1 2,767 | 86.67 | 49.32 | |
1,754.10 | 75,554.39 | 121.58 | 7,735.50 | -17.93 | 617 | 1.47 | 67.24 | |
2,300.10 | 69,280.47 | 47.16 | 6,967.00 | 60.74 | 1,389 | 15.34 | 67.03 | |
1,774.00 | 64,503.04 | #1 28.49 | 5,474.20 | 13.60 | 2,226 | 29.00 | 65.15 | |
1,700.00 | 60,790.51 | 46.33 | 3,964.50 | -3.54 | 1,302 | 1.97 | 64.58 | |
1,039.70 | 25,418.90 | 31.25 | 5,313.50 | 4.92 | 681 | 47.96 | 68.60 | |
645.00 | 22,140.31 | 50.29 | 2,100.30 | 38.11 | 422 | 38.35 | 50.55 | |
1,601.40 | 17,122.85 | 113.37 | 4,162.80 | 29.36 | 95 | 177.78 | 59.71 | |
1,093.30 | 15,362.03 | 119.43 | 2,638.00 | #1 99.15 | 101 | #1 405.88 | 55.45 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
39.80 %
Net Income Growth
55.65 %
Cash Flow Change
280.65 %
ROE
45.41 %
ROCE
42.24 %
EBITDA Margin (Avg.)
8.02 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 619 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 |
| Fixed Assets | 169 | 162 | 171 | 179 | 209 | 225 | 265 | 297 | 321 | 369 | 409 |
| Current Assets | 161 | 169 | 191 | 187 | 99 | 163 | 102 | 143 | 172 | 137 | 205 |
| Capital Work in Progress | 3 | 0 | 0 | 0 | 0 | 3 | 6 | 0 | 0 | 1 | 0 |
| Investments | 12 | 589 | 732 | 913 | 1,001 | 1,133 | 2,047 | 2,208 | 1,754 | 1,786 | 1,900 |
| Other Assets | 435 | 124 | 89 | 67 | 56 | 110 | 91 | 127 | 130 | 173 | 194 |
| Total Liabilities | 619 | 876 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 |
| Current Liabilities | 53 | 58 | 68 | 59 | 49 | 46 | 59 | 68 | 84 | 90 | 111 |
| Non Current Liabilities | 38 | 15 | 13 | 14 | 9 | 7 | 53 | 68 | 43 | 53 | 54 |
| Total Equity | 528 | 803 | 911 | 1,086 | 1,209 | 1,418 | 2,297 | 2,497 | 2,078 | 2,186 | 2,339 |
| Reserve & Surplus | 474 | 750 | 858 | 1,032 | 1,157 | 1,367 | 2,246 | 2,445 | 2,027 | 2,134 | 2,287 |
| Share Capital | 53 | 53 | 53 | 53 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 2 | -0 | 0 | -2 | 1 | 57 | -52 | -5 | -0 | 0 | 2 |
| Investing Activities | 5 | -5 | -47 | -22 | 68 | 57 | -35 | 19 | 7 | 26 | -27 |
| Operating Activities | 22 | 10 | 52 | 24 | 22 | 7 | -2 | -18 | 39 | 23 | 86 |
| Financing Activities | -25 | -5 | -5 | -3 | -89 | -6 | -15 | -6 | -46 | -48 | -58 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % | 70.88 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.07 % | 1.43 % | 1.97 % | 1.78 % | 1.66 % | 1.50 % | 1.38 % |
| DIIs | 4.34 % | 4.75 % | 4.88 % | 5.16 % | 4.68 % | 4.29 % | 4.12 % | 3.96 % | 3.96 % | 3.94 % | 3.41 % | 0.04 % | 0.05 % | 0.05 % | 0.09 % | 0.06 % | 0.05 % | 0.05 % | 0.05 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.84 % | 19.98 % | 20.05 % | 18.10 % | 18.39 % | 19.07 % | 19.40 % | 19.47 % | 19.51 % | 19.40 % | 19.66 % | 22.55 % | 22.22 % | 21.70 % | 21.56 % | 21.76 % | 21.94 % | 22.21 % | 22.29 % |
| Others | 4.94 % | 4.38 % | 4.18 % | 5.85 % | 6.04 % | 5.76 % | 5.60 % | 5.69 % | 5.65 % | 5.77 % | 6.05 % | 6.53 % | 5.78 % | 5.94 % | 5.50 % | 5.52 % | 5.47 % | 5.36 % | 5.40 % |
| No of Share Holders | 67,238 | 77,201 | 80,561 | 78,381 | 80,135 | 83,006 | 83,612 | 83,659 | 82,339 | 81,732 | 82,947 | 94,012 | 99,130 | 98,478 | 1,02,249 | 1,07,423 | 1,06,732 | 1,07,510 | 1,06,470 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.2 | 0.2 | 0.2 | 0.6 | 0.2 | 1.8 | 2.2 | 2.4 | 2.4 |
| Dividend Yield (%) | 0.00 | 0.46 | 0.58 | 0.57 | 0.58 | 0.28 | 3.19 | 2.64 | 2.44 | 2.39 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 31 Jul 2021 |  Dividend | ₹ 0.20 /share | 29 Jul 2021 | 133.40 | 120.65 |
| 13 Sept 2022 | Dividend | ₹ 1.80 /share | 12 Sept 2022 | 75.60 | 73.60 |
| 03 Aug 2023 | Dividend | ₹ 2.20 /share | 03 Aug 2023 | 65.02 | 80.63 |
| 05 Aug 2024 | Dividend | ₹ 2.40 /share | 05 Aug 2024 | 88.29 | 146.75 |
| 12 Aug 2024 |  Annual General Meeting | NA | 12 Aug 2024 | 104.16 | 144.07 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 122.59 | 134.38 |
| 07 Feb 2025 | Quarterly Result Announcement | NA | 07 Feb 2025 | 110.15 | 116.55 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 99.96 | 104.35 |
| 05 Aug 2025 | Dividend | ₹ 2.40 /share | 05 Aug 2025 | 104.35 | 114.45 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 112.25 | 108.90 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 119.45 | 108.90 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
Oct 15, 2025
Oct 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Intimation For Change Of Email Address Of The
Registrar And Share Transfer Agent Of The CompanyOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 20, 2025
Sep 20, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 19, 2025
Sep 19, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 12, 2025
Aug 12, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Aug 12, 2025Proceedings Of 118Th Annual General Meeting Held On 12Th August 2025Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Aug 12, 2025Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 12, 2025
Aug 12, 2025Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter Ended 30Th June 2025Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Jul 31, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Jul 05, 2025Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March 2025Jul 04, 2025
Jul 04, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Jul 04, 2025Reg. 34 (1) Annual Report.Jul 04, 2025
Jul 04, 2025Notice Of 118Th Annual General Meeting Of The Company To Be Held On 12Th August 2025Jul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 03, 2025
Jun 03, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations 2015")May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Intimation For Amendments Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationMay 13, 2025
May 13, 2025Appointment Of Secretarial Auditors Of The CompanyMay 13, 2025
May 13, 2025Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 13, 2025
May 13, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 09, 2025
May 09, 2025Board Meeting Intimation for Considering Audited Financial Results For The Quarter And Financial Year Ended 31St March 2025May 02, 2025
May 02, 2025Intimation For Change Of Email And Website Address Of The Registrar And Share Transfer Agent (RTA) Of The CompanyApr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Apr 07, 2025Clarification On Increase In VolumeApr 04, 2025
Apr 04, 2025Clarification sought from Alembic LtdApr 04, 2025
Apr 04, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 22, 2025
Mar 22, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-RetirementFeb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 20, 2025
Feb 20, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 19, 2025
Feb 19, 2025Technical Indicators
RSI(14)
Neutral 46.99
ATR(14)
Less Volatile 2.44
STOCH(9,6)
Neutral 55.24
STOCH RSI(14)
Neutral 66.90
MACD(12,26)
Bullish 0.24
ADX(14)
Weak Trend 19.55
UO(9)
Bearish 46.43
ROC(12)
Uptrend And Accelerating 2.13
WillR(14)
Neutral -42.03
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
